CTVA

Corteva is a durable, well-capitalized crop science franchise, but the numbers describe a slow grower, not a compounder. FY2025 revenue of $17.4B rose just 2.9% and is essentially flat versus 2022's $17.5B — four years of top-line stagnation. GAAP profitability is thin (6.3% net margin, 4.5% ROE), and net income of $1.09B remains far below the $1.76B earned in 2021, so the reported earnings recovery (+20.6%) is really a bounce off a depressed 2023 trough ($735M). At $84.69 the stock trades at 52.9x diluted EPS of $1.60, an expensive multiple for a business growing low-single-digits and earning a sub-5% return on its $24.1B equity base.

The more constructive read is cash. Operating cash flow jumped 58.8% to $3.41B against only $591M of capex, implying roughly $2.8B of free cash flow — far above GAAP net income, because heavy amortization from the DuPont separation depresses reported EPS and inflates the headline P/E. On a price-to-FCF basis (~20x) the valuation is defensible rather than egregious. The balance sheet is a genuine strength: $4.52B cash (+45.6%), $24.1B equity, current assets covering current liabilities 1.4x, and only $782M of current debt. Management is returning capital — $1.07B of buybacks (shares -1.9%) plus $475M of dividends — which supports the shares without stretching finances. The slightly negative retained earnings (-$67M) is a legacy artifact of the spin, not a solvency signal.